E2-2 and E2A (Hsu et al., 1991; Voronova and Lee, 1994; Goldfarb et al., 1996) . By analogy with the myogenic The product of the scl (also called tal-1 or TCL5) gene is bHLH proteins, it has been speculated that scl exerts its a basic domain, helix-loop-helix (bHLH) transcription biochemical function by binding DNA in a sequencefactor required for the development of hematopoietic specific fashion and activating transcription of target genes cells. Additionally, scl gene disruption and dysregula- (Green, 1996; Porcher et al., 1996; Robb et al., 1996) .
tion, by either chromosomal translocations or a site-
Several reports have demonstrated that scl is expressed specific interstitial deletion whereby 5Ј regulatory primarily in hematopoietic and vascular endothelial cells elements of the sil gene become juxtaposed to the (Green et al., 1992; Hwang et al., 1993; Kallianpur et al. , body of the scl gene, is associated with T-cell acute 1994; Pulford et al., 1995) , although fetal brain tissue lymphoblastic leukemia (ALL) and T-cell lymphoalso expresses easily detectable levels of scl mRNA (Green blastic lymphoma. Here we show that an inappropri et al., 1992) . Recent experiments with mice harboring a ately expressed scl protein, driven by sil regulatory targeted deletion of scl have demonstrated that the scl elements, can cause aggressive T-cell malignancies in gene product is needed for all hematopoietic development, collaboration with a misexpressed LMO1 protein, thus including T and B lymphocytes (Robb et al., 1995b ; recapitulating the situation seen in a subset of human Shivdasani et al., 1995; Porcher et al., 1996) . These T-cell ALL. Moreover, we show that inappropriately findings have led to the speculation that scl expression is expressed scl can interfere with the development of required for commitment of ventral mesoderm to hematoother tissues derived from mesoderm. Lastly, we show poietic progenitor cells (Porcher et al., 1996) . that an scl construct lacking the scl transactivation Non-random chromosomal translocations are a recurrent domain collaborates with misexpressed LMO1, demontheme in hematopoietic malignancies; in T-cell acute strating that the scl transactivation domain is dispenslymphoblastic leukemia (T-cell ALL) and lymphoblastic able for oncogenesis, and supporting the hypothesis lymphoma of T-cell phenotype, the translocations oftenIntroduction known as TTG1 or RBTN1) (McGuire et al., 1989; Boehm et al., 1991) , LMO2 (formerly known as TTG2 or RBTN2) The scl gene (also known as TCL5 or tal-1) was first identi- (Boehm et al., 1991; Royer-Pokora et al., 1991) or scl fied by virtue of its involvement in a t(1;14)(p33;q11) trans- Chen et al., 1990; Finger et al., location present in the multipotential DU528 stem cell 1990) . In general, these genes are not highly expressed in leukemia cell line Finger et al., 1989;  normal T cells, but T cells which have undergone a Chen et al., 1990) . The scl gene product contains the translocation involving one of these genes express the 'bHLH' (basic domain, amphipathic α-helix, loop, amphitranslocated gene at relatively high levels . pathic α-helix) motif, conserved in a wide array of It has been proposed that inappropriate expression of these eukaryotic transcription factors in organisms ranging from transcription factors, in a T-cell millieu, leads to malignant baker's yeast to man (Murre et al., 1989; Olson and transformation, possibly through direct transcriptional Klein, 1994) . A transcription activation domain has been activation of target genes. While scl translocations are identified at the amino-terminal portion of the scl protein (Hsu et al., 1994b; Sanchez-Garcia and Rabbitts, 1994;  present in only 3% of T-cell ALL patients (Carroll et al., 1990) ,~25% of T-cell ALL patients activate scl by a sitespecific interstitial deletion which replaces the scl 5Ј regulatory sequences with those of an upstream gene, sil (Aplan et al., 1990b; Brown et al., 1990) . In addition, T-cell ALL cell lines and patient samples with no detectable scl gene rearrangments often express high levels of scl mRNA; one report has demonstrated ectopic scl mRNA expression in a majority (60%) of T-cell ALL patients (Bash et al., 1995) . Despite the striking association of scl gene activation with T-cell ALL, until recently, there has been little evidence presented to demonstrate direct proof that scl gene activation leads to malignant transformation. Two groups demonstrated that transgenic mice overexpressing scl did not develop T-cell malignancies (Robb et al., 1995a , Larson et al., 1996 , nor did lethally irradiated mice reconstituted with bone marrow engineered to overexpress scl (Elwood and Begley, 1995) . However, when scl transgenic mice were crossed with mice engineered to overexpress LMO2, the offspring positive for both scl and LMO2 developed T-cell malignancies 3 months earlier than did mice transgenic only for LMO2, indicating a collaborative effect of scl and LMO2 (Larson et al., 1996) . More recently, 28% of mice transgenic for a construct which expressed a full-length scl protein driven by an lck promoter developed T-cell malignancies within 350 days, producing clear evidence that scl was a proto-oncogene (Kelliher et al., 1996) . The onset and penetrance of disease was significantly increased when these mice were crossed with transgenic mice which overexpress casein kinase IIα (Kelliher et al., 1996) . Several investigators have 1994; Green, 1996; Kelliher et al., 1996; Porcher et al., Northern blot analysis of four independent stable transfectants of the 1996). F4-6 murine erythroleukemia cell line hybridized to a human scl Here we describe generation of transgenic mice using cDNA probe (1.0SX). The 28S and 18S rRNA bands are indicated; exogenous scl mRNA is indicated with an arrow. The human scl probe constructs which express scl mRNA driven by a sil cross-hybridizes with the endogenous murine scl, and is seen as a promoter, thus mimicking the most common type of scl band which co-migrates with the 28S rRNA. The transfectants in lanes gene dysregulation associated with human T-cell ALL.
1 and 2 express transfected scl; those in lanes 3 and 4 express little, if
We demonstrate that mice transgenic for either a fullany, exogenous scl. length or an amino-terminal truncated scl driven by a sil promoter surprisingly display bony abnormalities and growth retardation, but do not develop T-cell malignancies.
promoter to target scl expression to thymocytes (Robb et al., 1995a) , we decided to use sil regulatory elements However, when crossed with mice that overexpress LMO1 in the thymus, enforced expression of an amino-terminal to drive scl expression, thus recapitulating the most common situation seen in human T-cell ALL patients. In truncated scl, which lacks the scl transactivation domain, leads to aggressive T-cell malignancies at an early age.
order to accomplish this goal, we isolated a human sil promoter, demonstrated it was functional when integrated These experiments demonstrate that the transactivation domain of scl is dispensible for leukemogenesis, and in the mouse genome, and searched for alternate forms of sil-scl fusion mRNA species in malignant T cells which suggest that scl is not acting by activating transcription of its normal target genes, but instead is more likely to had undergone a sil-scl rearrangement. A 2.4 kb human genomic sil fragment which encompassed the predicted act through a dominant-negative mechanism.
sil transcript initiation site (Aplan et al., 1991) was isolated and shown to activate a CAT reporter gene in transient
Results
transfection assays using human and murine cell lines. This promoter fragment was then used to produce the Generation of constructs recapitulating sil and scl recombination pSIL/SCL and pSIL/TSCL vectors ( Figure 1A ). Since this promoter had not been used previously in transgenic Since we were aware of reports demonstrating a lack of oncogenicity in transgenic mouse models using the CD2 experiments, we verifed that the sil promoter fragment remained functional when incorporated into the mouse since amplification of the same mRNA templates used in Figure 2 with sil exon 1 and scl exon 3 primers generated genome by transfecting the pSIL/SCL vector into murine erythroleukemia cells and selecting stable transfectants.
quantities of a sil exon 1-scl exon 3 PCR product that were roughly equivalent to the amount of sil exon 1--scl Fourteen of 20 randomly selected clones expressed easily detectable amounts of exogenous scl mRNA (Figure 1b) , exon 5 PCR products generated by sil exon 1 and scl exon 6 primers. The pSIL/TSCL vector ( Figure 1a ) demonstrating that the human sil promoter was functional when integrated into the mouse genome.
recapitulates the sil exon1-scl exon 5 fusion, and encodes a truncated 22 kDa scl protein that lacks the scl transactivOur initial experiments used the pSIL/SCL construct, which produced the full-length scl protein. While the ation domain and inititiates transcription at scl residue 176, similar to the protein product produced by scl exon1a-initial cohort of mice generated with this construct was under observation, we investigated the possibility that exon5 transcripts in normal cells (Bernard et al., 1991; Cheng et al., 1993) . alternately spliced forms of the fusion sil-scl mRNA may exist. We were especially interested in this possibility since the intact scl locus normally generates a complex Phenotype of mice generated with the pSIL/SCL vector pattern of alternately spliced transcripts, including one which produces an amino-terminal truncated form of the Four founder animals were obtained by injection of the pSIL/SCL construct. Founder A1 and A4 both incorporated scl protein (Aplan et al., 1990a) . We had previously used RNase protection probes to demonstrate the production of one copy of the transgene and expressed relatively low levels of the transgene in thymus, liver and spleen sil exon 1-scl exon 3 fusion mRNA species in leukemic cells which displayed a sil-scl recombination (Aplan et al., ( Figure 3 ). Founder A2 incorporated two copies of the transgene and expressed 5-fold higher levels of exogenous 1990b). Since this fusion occurs in the 5Ј-untranslated region (UTR) of both genes, the net effect of the sil exon scl mRNA. Founder A3 incorporated three copies of the transgene, but never transmitted the transgene, and mRNA 1-scl exon 3 fusion is the production of a fusion mRNA encoding a full-length scl protein.
expression was never assayed. Only one of 180 positive progeny of these three founders developed a T-cell maligWe employed an RT-PCR assay that utilized an scl exon 6 primer and a sil exon 1 primer. Several amplification nancy over an observation period lasting 16 months (see below). products were obtained as depicted in Figure 2 ; the predominant amplification product corresponded to a sil Continued observation of these mice revealed an unexpected phenotype. Nine (3/34) and eight (5/62) percent exon 1-scl exon 5 fusion. Although a sil exon 1-scl exon 3 product could theoretically have been amplified of the scl-positive progeny from lines A1 and A4 had obviously kinked tails (Figure 4a ), while being otherwise with these primers, we could not detect an amplification product corresponding to a sil exon 1-scl exon 3 fusion healthy. All but one (5/6) of the positive progeny of line A2, the line with the highest scl mRNA expression, using these primers. This may be due to competition with the smaller sil-scl fusion mRNAs, or to difficulty in displayed kinked tails in conjunction with more severe abnormalities, including growth retardation, sparse hair reverse transcribing through GC-rich scl exon 4 sequences, and infertility (Figure 4a ). The females all had an atretic one of these 15 developed an agressive T-cell malignancy at age 15 months. Taken together, these data suggest that vaginal opening that could not be probed, while the only male was unable to impregnate any females despite ectopic scl expression causes bony abnormalities in a dose-dependent fashion, and that higher levels of ectopic numerous attempts at mating. It is of note that Southern blot analysis of genomic DNA from the only transgenic scl expression are associated with embryonic lethality. offspring of line A2 which did not display this unusual phenotype demonstrated that the transgene had been Phenotype of mice generated with an scl construct lacking the transactivation domain rearranged and largely deleted. None of Ͼ300 nontransgenic offspring observed during this period had tail
The fact that mice transgenic for a full-length scl were not developing T-cell malignancies led us to investigate kinks. Alizarin red/alcian blue staining showed the only obvious bony abnormality of these animals to be within the possibility that the amino-terminal truncated p22 scl isoform was the oncogenic form. In addition to being the tail vertebrae (Figure 4a ). In addition, while lines A1 and A4 transmitted the transgenic allele in expected formed by a sil exon1-scl exon 5 fusion mRNA, the p22 scl protein can also be produced from T-cell ALL cells Mendelian fashion, line A2, which expressed the highest level of exogenous scl mRNA, transmitted the transgene through the use of an alternate scl promoter, which initiates transcription from within scl exon 4 (Aplan et al., 1990a ; to only six of 45 progeny.
To evaluate a potential dosage effect of scl transgene Bernard et al., 1992 Bernard et al., , 1996 . Therefore, we generated four additional founder lines using the pSIL/TSCL construct. expression on the generation of this phenotype, we crossed two line A4 animals. Ten of 11, seven of 39, and none of Line A5(3) expressed the highest level of exogenous scl and had incorporated 5-7 copies of the transgene. Similar 18 animals with two, one or zero copies of the transgene, respectively, displayed tail kinks. Additionally, four of the to the pSIL/SCL founders, 0/33, 3/29, 4/18 and 2/27 positive offspring of lines A5(1), A5(2), A5(3) and A5(4), animals with two copies of the transgene were growth retarded and had sparse hair (Figure 4b ). None of these respectively, demonstrated kinked tails. Also, while lines A5(1), A5(2) and A5(4) transmitted the transgene within animals developed a T-cell malignancy over a 16 month observation period. Some of these double-positive (A4ϩ/ the range expected for Mendelian inheritance, only 18/86 (21%) of the A5(3) offspring were transgenic, again A4ϩ) animals were fertile; one of these was crossed with a line A1-positive animal (A1ϩ/A1-). Of 46 offspring suggesting the possibility of embryonic lethality. None of the 107 positive progeny of these founders have developed from this cross, 31 were A4ϩ/A1-; two of these had kinked tails; 15 offspring (only half of the expected T-cell malignancies over a 12 month observation period. number) were A4ϩ/A1ϩ, nine of these had kinked tails; scl does not collaborate with pim-1 to induce lck-LMO1 mice with a line expressing the truncated form of scl to investigate whether the scl transactivation domain T-cell malignancies In order to determine if scl was able to cooperate with would be required for malignant transformation. As seen in Figure 5a , 19/20 (95%) of mice positive for both scl other known transforming genes, we crossed offspring of the A4 line with mice transgenic for an Eμ-pim-1 construct.
and LMO1 developed an aggressive T-cell leukemia/ lymphoma by age 6 months. In contrast, none of the pim-1 was chosen as a candidate gene since it was identified initially by virtue of its frequent activation at mice positive for scl or LMO1 alone developed T-cell malignancies during the 6 month observation period. MuLV insertion sites in murine T-cell lymphomas (Cuypers et al., 1984) , and has been shown to accelerate
The mice who developed leukemia/lymphoma typically displayed labored breathing, lethargy, peripheral lymphdramatically lymphoid malignancies produced by the bHLH proteins c-Myc and N-Myc (van Lohuizen et al., adenopathy, thymic enlargement, splenomegaly and hepatomegaly ( Figure 5b ). Microscopic exam showed 1989). We have now followed a cohort of mice positive for both scl and pim-1 for Ͼ1 year, and compared them widespread organ infiltration, including liver, kidney, lung and bone marrow; the infiltration of solid tissues such as with control groups positive for either scl or pim-1 only, or negative for both transgenes. Two of eight sclϩ/pim-1ϩ kidney and liver was typically in a perivascular pattern (Figure 5c ). Bone marrow samples were largely replaced animals have developed non-T-cell malignancies over a 15 month observation period; three of 17 scl-/pim-1ϩ mice by lymphoblasts; complete blood counts generally showed a low red blood cell count, a low platelet count and a have developed malignancies (one spindle cell sarcoma of unknown primary, two T-cell lymphomas), and none of normal or increased white blood cell count. The immunophenotypes were typical of immature T-cell leukemia/ 15 sclϩ/pim-1-mice have developed T-cell malignancies. We conclude that ectopically expressed scl does not lymphoma and are presented in Table I . The malignant cells expressed both scl and LMO1 (Figure 6a ) mRNA. accelerate the rate at which pim-1 transgenic mice develop malignancies.
Western blot analysis using a monoclonal scl antibody (Pulford et al., 1995) demonstrated the presence of a 22 kDa scl protein in tumor tissue (data not shown); The p22 isoform of scl collaborates with LMO1 to induce an aggressive T-cell leukemia/lymphoma lymphomas from the lck-LMO1 mice have been shown previously to express LMO1 by immunohistochemistry In order to determine if scl could cooperate with LMO1 to induce T-cell ALL, we crossed the A5(3) line with (McGuire et al., 1992) . The presence of TCRβ gene rearrangments was evaluated on a subset of the tumors mice engineered to express LMO1 from an lck promoter (McGuire et al., 1992) . LMO1 was chosen as a candidate and demonstrated clonal patterns of TCRβ rearragements ( Figure 6b ). As further evidence of their malignant nature, since a subset of T-cell ALL patients and cell lines have activated both scl and LMO1 . In cells from a subset of these tumors have been cultured in vitro for several months without the addition of hematoa previous report, 50% of the progeny of lck-LMO1 line 11 developed T-cell leukemia/lymphoma at ages ranging poietic growth factors.
Since the T-cell leukemia/lymphomas were not evident from 5 to 16 months; the incomplete penetrance and relatively long latency period led to the speculation that until 12 weeks at the earliest, it is conceivable that additional mutational events are required for malignant additional genetic events were required to produce a frank malignancy (McGuire et al., 1992) . We chose to cross the transformation of the scl/LMO1ϩ cells. Given the frequent
Discussion
In this study, we demonstrate a role for scl deregulation in generating aggressive T-cell malignancies. The immunophenotype and clinical manifestations of disease in the scl/LMO1 double positive mice is quite similar to that recognized in human patients with T-cell ALL. The fact that all but one of a cohort of 20 double-positive mice developed T-cell leukemia/lymphoma within a relatively short time span indicates that scl and LMO1 can cooperate quite effectively to induce T-cell malignancies. Moreover, given that both of these genes were originally identified at chromosome translocation breakpoints, and that both of these genes are activated in human T-cell leukemias, this would seem to be a valid, useful murine model of the human disease. In order to simulate the situation seen in human T-cell ALL, we generated transgenic mice which ectopically expressed either a full-length or an amino-terminal truncated scl protein under the control of sil regulatory elements. We focused our later experiments on the sil exon1-scl exon 5 fusion splice form, since it was one of the more abundant forms, and encoded a truncated scl gene product which lacked the scl transactivation domain. This finding, together with the observation that some T-cell ALL patients produce a truncated scl transcript encoding a protein which lacks the scl transactivation domain (Bernard et al., 1992; Goldfarb and Greenberg, 1994) , suggested that the scl transactivation domain may be dispensable for oncogenesis.
An unexpected finding was the observation that mice transgenic for either the full-length or truncated form of the scl gene product developed bony abnormalities and growth retardation, in what seemed to be a dose-dependent fashion. We initially would not have expected the sil promoter to be functional in non-hematopoietic tissues, based on reports (Aplan et al., 1991) that suggested sil expression was limited to hematopoietic tissues. However, additional studies have demonstrated that sil mRNA is ubiquitously expressed in proliferating cells, and seems to be an immediate early response gene (Collazo-Garcia et al., 1995; Izraeli et al., 1995) . Seen in this light, one would expect the sil promoter to be active, and generate ectopic scl production, in all proliferating tissues of the transgenic mouse. The most consistent and obvious phenotypic effect of ectopic scl expression was the incomplete formation of tail vertebrae. Numerous animals from domain, it retains the potential to bind and sequester those proteins which normally bind scl through its HLH domain.
As mentioned above, the fact that some animals did homozygous deletions of p16 in human T-cell ALL and not develop clinical signs of disease until 6 months of lymphoblastic lymphoma (Hirama and Koeffler, 1995) , age was consistent with the possibility that additional we probed Southern blots of tumor tissue with a PCRgenetic events were required for leukemic transformation. generated p16 probe. No samples showed evidence of a homozygous deletion of p16 (data not shown).
Given the likely importance of the interactions between p16, CDK4, D-type cyclins and pRB in T-cell leukemia/ lymphoma (Hirama and Koeffler, 1995) , these proteins would seem to be reasonable candidates for the proposed additional events. However, a preliminary analysis of the genes coding for p16 and pRB did not reveal any gross abnormality (deletion or rearrangement) at the Southern blot level. A more thorough analysis of these proteins as potential candidates is currently underway. Several investigators (Green, 1996; Kelliher et al., 1996; Porcher et al., 1996) have speculated that the oncogenic potential of dysregulated scl may be conferred either through inappropriate activation of physiologic scl target genes, or through a dominant-negative mechanism, where misexpressed scl binds to and functionally inactivates those proteins to which it normally binds (Figure 7) . Our data suggests that scl is unlikely to exert its oncogenic potential through inappropriate activation of target genes, since mice transgenic for a sil-scl fusion mRNA lacking the scl transactivation domain developed aggressive T-cell leukemia/lymphomas. This finding supports the notion that scl is likely to be oncogenic through a dominant- pressor genes (Schenker et al., 1994) , has been recovered Note that although this model depicts scl binding to a HLH protein, recently as an scl-binding protein in a yeast two-hybrid scl has been shown to bind non-HLH proteins and could exert a dominant-negative action by binding one of these non-HLH proteins screen for scl-binding proteins (Mahajan et al., 1996) . shown to bind scl using both co-immunoprecipitation and still act in a dominant-negative fashion with respect to the HLHX two-hybrid assays (Wadman et al., 1994) , and mice protein. Preliminary results suggest that mice transgenic for both a transgenic for both scl and either LMO1 (this report) or full-length scl protein and LMO1 develop T-cell leukemia/lymphoma at approximately the same rate as mice transgenic for the truncated scl LMO2 (Larson et al., 1996) leukemia/lymphomas. However, although scl and LMO1 clearly cooperate in the genesis of T-cell malignancies, it remains possible that this cooperativity does not need to appears to repress the transactivation domain of the take place through a direct interaction, but that scl and E-proteins (Hofmann and Cole, 1996) has been identified, LMO1 may instead be acting through different pathways.
making the E-proteins likely candidates for scl sequestraScl binding with E-proteins through HLH domain tion and functional inactivation in a dominant-negative interactions has been demonstrated by several laboratories; model. a recent report (Zhuang et al., 1996) has studied mice
In summary, we have demonstrated that scl and LMO1 lacking either E2-2, E2A or HEB . Mice can cooperate to generate aggressive T-cell malignancies lacking E2-2 appeared to have normal T-cell development, in a mouse model of human T-cell ALL. The oncogenic while mice lacking HEB demonstrated abnormal fetal and effect of scl can be produced by an amino-terminal neonatal T-cell development, primarily manifested by a truncated form of the scl protein which lacks the scl lack of CD4 and CD5 expression in thymocytes. Interesttransactivation domain and is commonly found in T-cell ingly, whereas CD4 and CD8 expression on thymocytes ALL, demonstrating that the scl transactivation domain is from 5-week-old mice positive for either an scl or LMO1 dispensable for its oncogenic action. Furthermore, mice transgene is similar to that seen with negative control transgenic for either the full-length or truncated scl display animals, thymocytes from scl/LMO1 double-positive mice developmental abnormalities in additional mesodermalso show decreased numbers of CD4-positive cells derived tissues. Although other models cannot be excluded, (D.S.Chervinsky and P.D. Aplan, unpublished data) . It is the most likely model that accounts for both malignancies not known whether mice lacking HEB are prone to and bony abnormalities using constructs which lack the developing T-cell malignancies as they generally die of scl transactivation domain is one which asserts that scl undefined causes before weaning (Zhuang et al., 1996) . In addition, a region within the scl carboxy-terminus that acts in a dominant-negative fashion.
into zygotes derived from a C57 Bl/10Ros-p d ϫC3H/HeRos cross (BCF1).
Materials and methods
Founders were identified by Southern blot analysis of DNA from tail biopsy and lines established by mating with BCF1 animals. Transgenic Plasmid construction mice were maintained on Harlan Teklad Laboratory Rodent Diet. Mice The pSIL/SCL plasmid was generated as follows. A 2.4 kb SstII-SstII transgenic for an Eμ-pim-1 construct (van Lohuizen et al., 1989) were human sil genomic fragment encompassing the sil transcript initiation obtained from GenPharm International. Mice transgenic for a lck-LMO1 site was isolated from a genomic sil clone (Aplan et al., 1991) ; the 5Ј construct (line 11 of McGuire et al., 1992) have been described previously. SstII site is derived from the pBS II (Stratagene) polylinker, the 3Ј SstII site is located within sil exon 1. This SstII fragment was then cloned into the SstII site of pBSII, and a HindIII-HindIII fragment from the Alizarin staining pMSCL-WT vector containing (i) an scl cDNA Mouse skeletons were stained using a modification of previously encoding the full-length human scl protein; (ii) a human β-globin described techniques (Kimmel and Trammell, 1981) . Briefly, animals fragment encompassing 18 bp of β-globin exon 2 and all of exon 3 were skinned and eviscerated; the skeletons dehydrated in 95% ethanol (including the polyadenylation signal); and (iii) a neomycin resistance for 24 h, defatted in acetone for 5 days, and stained for 6 h at 37°C cassette, was cloned into the HindIII site of pBSII, immediately downusing a 70% ethanol/acetic acid/saturated alizarin red/0.14% alcian blue stream of the sil promoter fragment. The vector was sequenced to verify solution. The skeletons were cleared in 1% KOH for 2-5 days and fixed its orientation. The pSIL/TSCL was constructed in three steps. First, using stepwise incubations with 20, 50 and 80% glycerol in 1% KOH. RT-PCR was used to amplify a sil exon 1-scl exon5 fusion from a cell
The skeletons were stored in 100% glycerol. line (CEM) known to contain a sil-scl fusion (Aplan et al., 1990b) , using oligonucleotides A and B (see below). This PCR product was
Immunophenotype and Western blot analysis cloned into the PCRII (Invitrogen) vector and sequenced to verify that Cells were immunophenotyped using monoclonal antibody conjugates no PCR artefacts had been introduced. Next, a 0.3 kb insert from this and standard techniques. Briefly, 10 6 cells were blocked with 1 μg of plasmid containing sil exon 1, scl exon 5 and a portion of scl exon 6 rat IgG for 15 min at 4°C followed by the addition of 1 μg of the was excised with SstI [the 5Ј SstI site was derived from the PCRII indicated monoclonal antibody conjugate for 45 min at 4°C. Cells polylinker, the 3Ј SstI site is within scl exon 6 (nucleotide 354 of DDBJ/ were washed twice in ice-cold phosphate-buffered saline (PBS) and EMBL/GenBank accession No. M29038)] and ligated in-frame to a 9 kb resuspended in 1% buffered formalin until analysis. Data was scored SstI fragment derived from the pSIL/SCL vector containing (i) human and analyzed using a FACScan analyzer (Beckton-Dickinson). Five scl exon 6 sequences, (ii) human β-globin exon 2 and 3 as above, (iii) a thousand events were acquired for each sample. The antibodies used neomycin resistance cassette, and (iv) the pBSII plasmid backbone.
were anti-mouse CD3R-PE, CD4-FITC and CD8-Red613 (GIBCO/ Lastly, the 2.4 kb SstII-SstII sil promoter fragment was then cloned into BRL). For Western blots,~10 7 cultured cells were harvested, washed the SstII site (located within sil exon 1) of this plasmid, generating the once in ice-cold PBS, and resuspended in RIPA buffer (1ϫ PBS, 1% pSIL/TSCL plasmid. All cloning junctions were sequenced to verify NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing a cocktail of the construct.
proteinase inhibitors (1 mg/ml Pefabloc SC, 1 mM EDTA, 25 μg/ml leupeptin, 10 μg/ml pepstatin, 2.5 μg/ml aprotinin). Cells and organelles were disrupted in a hand-held glass Dounce homogenizer, incubated on Nucleic acid manipulations ice for 30 min and centrifuged at 14 000 r.p.m. for 30 min in a 4°C Genomic DNA was isolated from tumors and tail biopsies using microcentrifuge. The precipitates were discarded and the supernatants conventional techniques, Southern blots were performed as described aliquoted and stored at -80°C. Protein concentrations were determined previously (Aplan et al., 1990a) . Total RNA was isolated using Trizol by the Bradford method. Cell lysates from tissues were prepared as (BRL); Northern blots were performed as described previously (Collazoabove except that individual cells were first released and separated from Garcia et al., 1995) . Probes used in this study included a 1.2 kb HindIIItissues by brief homogenization in ice-cold PBS before they were XbaI human scl cDNA fragment (67HX, Aplan et al., 1992) , a 1.0 kb precipitated and resuspended in RIPA buffer. For Western blots, 100 μg SstI-XbaI scl cDNA probe (1.0SX, Begley et al., 1989) , a PCR-amplified of cell lysate protein was resolved by 15% SDS-PAGE (4% stacking human LMO1 cDNA fragment (nucleotides 544-957 of DDBJ/EMBL/ gel) and transferred electrophoretically (Towbin et al., 1979) to a Hybond GenBank accession No. M26682), a PCR-amplified murine p16 cDNA nitrocellulose membrane (Amersham). Blots were incubated at 4°C fragment (nucleotides 206-458 of DDBJ/EMBL/GenBank accession No.
overnight in 5% non-fat dry skim milk in TBS (50 mM Tris-HCl, L76150) and a 0.2 kb human TCR Cβ2 probe (gift of Dr Ilan Kirsch). pH 7.6, 150 mM NaCl) containing 0.05% Tween-20 (TBS-T). The blots The sil-scl fusion mRNA RT-PCR assay was accomplished using rTth were rinsed briefly with TBS-T and incubated at room temperature for DNA polymerase (Perkin Elmer Cetus). Briefly, 0.5 μg of total RNA 1 h with a human scl monoclonal antibody (antibody BTL73, kind gift from CEM or HSB2 (T-cell lines known to have undergone a sil-scl of Dr Karen Pulford). Immunoreactive proteins were revealed using recombination) or HL60 (a myeloid cell line used as a negative control) horseradish peroxidase-labeled anti-mouse IgG and ECL Western blotting was reverse transcribed using an scl exon 6 antisense oligonucleotide detection reagents (Amersham) by exposure to Kodak X-ray film. (primer C in Figure 1 ; 5Ј-ATGTGTGGGGATCAGCTTGC-3Ј) for 15 min at 70°C. A sil exon 1 sense oligonucleotide (primer A in Figure 1 ; 5Ј-GCTCCTACCCTGCAAACAGA-3Ј) was added followed by 35 PCR cycles of 60 s at 95°C, 60 s at 51°C and 90 s at 72°C, and a terminal
